ALK and neoplasm: Our results showed that 55% of EML4::ALK v3 tumors (11 of 20) had co-existing heterogeneous fusion subclones in the same tumors (7 two-subclone tumors, 3 three-subclone tumors, and 1 six-subclone tumor; Figures 5B and 5C), which was significantly higher than 19% (6 of 31) in other variant tumors (4 of 19 v1, 2 of 8 v5, and none of 4 v2; Fisher’s exact test, two-sided, p = 0.0143).